This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurumurthy, P.
Right arrow Articles by Paramesh, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurumurthy, P.
Right arrow Articles by Paramesh, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2004, p. 4473-4475, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4473-4475.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease

Prema Gurumurthy,1,{dagger} Geetha Ramachandran,1 A. K. Hemanth Kumar,1 S. Rajasekaran,2 C. Padmapriyadarsini,1 Soumya Swaminathan,1* S. Bhagavathy,1 P. Venkatesan,1 L. Sekar,1 A. Mahilmaran,2 N. Ravichandran,2 and P. Paramesh2

Tuberculosis Research Centre (Indian Council of Medical Research), Chetput,1 Government Hospital for Thoracic Medicine, Tambaram, Chennai, India2

Received 30 April 2004/ Returned for modification 2 July 2004/ Accepted 1 August 2004

We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.

* Corresponding author. Mailing address: HIV-AIDS Division, Tuberculosis Research Centre (Indian Council of Medical Research), Mayor V.R. Ramanathan Rd., Chetput, Chennai 600 031, India. Phone: 91-044-28362442. Fax: 91-044-28362528. E-mail: doctorsoumya{at}yahoo.com.

{dagger} Present address: K.J. Hospital Post Graduate & Research Foundation, Chennai, India.

Antimicrobial Agents and Chemotherapy, November 2004, p. 4473-4475, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4473-4475.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Barroso, E. C., Pinheiro, V. G. F., Facanha, M. C., Carvalho, M. R. D., Moura, M. E., Campelo, C. L., Peloquin, C. A., Guerrant, R. L., Lima, A. A. M. (2009). Serum Concentrations of Rifampin, Isoniazid, and Intestinal Absorption, Permeability in Patients with Multidrug Resistant Tuberculosis. Am J Trop Med Hyg 81: 322-329 [Abstract] [Full Text]  
  • Zhu, M., Bifano, M., Xu, X., Wang, Y., LaCreta, F., Grasela, D., Pfister, M. (2008). Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients. Antimicrob. Agents Chemother. 52: 2836-2841 [Abstract] [Full Text]  
  • Wilkins, J. J., Savic, R. M., Karlsson, M. O., Langdon, G., McIlleron, H., Pillai, G., Smith, P. J., Simonsson, U. S. H. (2008). Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption. Antimicrob. Agents Chemother. 52: 2138-2148 [Abstract] [Full Text]  
  • Ramachandran, G., Hemanthkumar, A.K., Rajasekaran, S., Padmapriyadarsini, C., Narendran, G., Anitha, S., Subramanyam, S., Kumaraswami, V., Swaminathan, S. (2007). Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 251-254 [Abstract]  
  • McIlleron, H., Norman, J., Kanyok, T. P., Fourie, P. B., Horton, J., Smith, P. J. (2007). Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother 60: 1398-1401 [Abstract] [Full Text]  
  • Ribera, E., Azuaje, C., Lopez, R. M., Domingo, P., Curran, A., Feijoo, M., Pou, L., Sanchez, P., Sambeat, M. A., Colomer, J., Lopez-Colomes, J. L., Crespo, M., Falco, V., Ocana, I., Pahissa, A. (2007). Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 59: 690-697 [Abstract] [Full Text]  
  • McIlleron, H., Wash, P., Burger, A., Norman, J., Folb, P. I., Smith, P. (2006). Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.. Antimicrob. Agents Chemother. 50: 1170-1177 [Abstract] [Full Text]  
  • Graham, S. M., Bell, D. J., Nyirongo, S., Hartkoorn, R., Ward, S. A., Molyneux, E. M. (2006). Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection. Antimicrob. Agents Chemother. 50: 407-413 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»